Citi raised the firm’s price target on Johnson & Johnson to $200 from $185 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened “positive catalyst watches” on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson to invest $2B in North Carolina with new facility
- Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
- Trump Trade: Pharma tariff announcement likely ‘weeks away’
- Pharma tariff announcement likely ‘weeks away,’ Reuters reports
- Trump, pharma industry discuss increasing medicine spending abroad, Reuters says